Docetaxel – Advanced breast cancer – as per NICE CG 80

Drug Name (Brand)	Docetaxel *(Taxotere®)*
Indication	Advanced breast cancer – as per NICE CG 80
Traffic Light Classification	Red
NICE TA (plus link)	Early and locally advanced breast cancer: diagnosis and treatment \| Guidance \| NICE
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. March 2009: The TAG acknowledged NICE Clinical Guideline 80 – Early and locally advanced breast cancer (Feb 2009), which specifies the place of docetaxel as part of adjuvant chemotherapy regimen for lymph node positive breast cancer. March 2009: TAG acknowledged NICE Clinical Guideline 81 Advanced Breast Cancer, which states that for patients with advanced breast cancer who are not suitable for anthracyclines (because they are contraindicated or because of prior anthracycline treatment either in the adjuvant or metastatic setting), systemic chemotherapy should be offered in the following sequence: * First line: single-agent docetaxel * Second line: single-agent vinorelbine or capecitabine * Third line: single-agent capecitabine or vinorelbine (whichever was not used as second-line treatment) Commissioning responsibility of NHS England SCG from April 2013. September 2014: The TAG noted NICE CG 81 (Update July 2014) – Advanced breast cancer: Diagnosis and treatment
Date of TAG recommendation / ratification		3/1/2009